Market Overview

RBC Says Chico's FAS Is An Under-Owned Name

Share:
RBC Says Chico's FAS Is An Under-Owned Name

Chico's FAS, Inc. (NYSE: CHS) reported a Q2 beat, with sales and margins ahead of expectations. The company represents an “under-owned name” with low expectations, RBC Capital Markets’ Brian Tunick said in a report. He reiterated an Outperform rating on the company, while raising the price target from $13 to $14.

Quarterly Beat

Chico’s FAS reported its adjusted EPS at $0.25, higher than the consensus estimate of $0.22. Sales declined 3.6 percent to $636 million, but came in ahead of the Street’s $632 million. The company’s EBIT margin came in at 8.5 percent, down from last year’s 9.2 percent, but beating the Street’s 7.4 percent, analyst Tunick mentioned.

Related Link: Investors Cheer Chico's FAS Q2 Earnings

Cushion For Meeting EBIT Margin Target

Chico’s FAS is creating a cost-cutting cushion to achieve its low-double-digit EBIT margin target, versus the 6.6 percent achieved in 2015, Tunick noted. CEO Broader announced another $25 million in cost savings, apart from the $65-$85 million announced in the prior quarter.

Positives

The EPS estimate for 2016 has been raised from $0.66 to $0.68. The analyst commented that Chico’s FAS was an “under-owned name w/lower expectations into 2Q16 print.” He enumerated the catalysts for the company as:

  • Lower expectations for 2H16 comp and GM
  • Cleaner inventory
  • Self-help for 2H16-2017 margin
  • September 28 analyst day

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for CHS

DateFirmActionFromTo
Aug 2019MaintainsEqual-Weight
Aug 2019MaintainsMarket Perform
Nov 2018MaintainsEqual-WeightEqual-Weight

View More Analyst Ratings for CHS
View the Latest Analyst Ratings

Posted-In: Brian Tunick RBC Capital MarketsAnalyst Color Long Ideas Price Target Reiteration Analyst Ratings Trading Ideas Best of Benzinga

 

Related Articles (CHS)

View Comments and Join the Discussion!

10 Conditions That Could Soon Be Treated With Cannabis: From Menstrual Cramps To Autism

Nobel Prize Winner Joseph Stiglitz On The 'Dishonest' EU-Apple Tax Beef